gPrescription drug brands dramatically increased their multiscreen TV advertising investment in the months following a sweeping federal enforcement action against deceptive pharmaceutical advertising, according to a May 2026 analysis by the Video Advertising Bureau (VAB). The report draws on Nielsen Ad Intel data covering January 2023 through March 2026 and offers one of the most detailed pictures available of how the FDA's September 2025 crackdown shaped pharma ad spending across broadcast, cable, and streaming platforms.

The headline finding is stark. In the six-month period from October 2025 through March 2026, pharma Rx brands spent $4.95 billion on multiscreen TV advertising, compared with $3.23 billion during the same period a year earlier - a 53% year-over-year increase, according to VAB. The number of distinct Rx advertisers active on TV during the period rose from 138 to 153, an 11% gain.

What the FDA did in September 2025

The regulatory backdrop matters. On September 9, 2025, the White House issued a presidential memorandum directing the Department of Health and Human Services and the FDA to step up enforcement of the Federal Food, Drug, and Cosmetic Act's provisions governing direct-to-consumer prescription drug advertising. HHS and the FDA responded the same day, announcing a wave of enforcement letters and signalling plans for rulemaking to close what the agencies described as an "adequate provision loophole" dating to 1997. That loophole had allowed pharmaceutical companies to meet disclosure obligations by pointing viewers to a website or toll-free number rather than including full risk information in the broadcast itself.

In total, the FDA sent more than 100 letters to pharmaceutical companies on September 9, 2025, according to VAB's analysis of FDA data. Of the formal "warning" letters issued - which carry a threat of enforcement action if violations are not corrected - 59 were directed at brand website content, and a further 34 "untitled" letters addressed TV advertising violations. The remaining letters covered online video, YouTube, sponsored links, webpages, promotional video, broadcast advertising, and print. Across the full set of warning letters, 96% were directed at digital platforms, assets, and practices, with TV advertising accounting for a comparatively small share.

The distinction between warning letters and untitled letters carries legal significance. According to VAB's analysis of FDA.gov data as of September 12, 2025, untitled letters are used for violations that do not meet the threshold of regulatory significance for a warning letter. Unlike a warning letter, an untitled letter does not include a statement warning the individual or firm that failure to promptly correct the violation may result in enforcement action.

Federal mandates governing pharma Rx advertisements require that promotions present a fair balance between a product's risks and benefits, avoid exaggerated claims, avoid creating a misleading overall impression, properly disclose financial relationships, and include information regarding major side effects and considerations. The September 2025 action represented a more aggressive enforcement posture than prior administrations had taken.

The counterintuitive spending response

The enforcement action produced a response that surprised some observers. Rather than pulling back from television, pharma brands accelerated investment - particularly in the months immediately following the crackdown. According to VAB, the FDA's letters effectively signalled that multiscreen TV remained a comparatively well-understood and compliant advertising environment for prescription drug brands, given that the vast majority of enforcement letters targeted digital and social platforms.

The quarterly data bear this out. In Q4 2025 - the quarter that directly followed the September crackdown - pharma Rx ad spend on multiscreen TV reached $1.86 billion, up 13% year-over-year from $1.64 billion in Q4 2024, according to VAB analysis of Nielsen Ad Intel data. The number of active Rx brands on TV rose from 122 to 140, a 15% increase. A year earlier, the equivalent quarter had actually seen a 1% spending decline and a 2% drop in brand count.

The acceleration continued into early 2026. Pharma Rx multiscreen TV spend in Q1 2026 reached $3.09 billion, a 94% year-over-year increase from $1.60 billion in Q1 2025. The number of active brands increased from 120 to 132, a 10% gain. That Q1 2026 figure was also substantially above Q1 2024's $1.72 billion and Q1 2023's $1.28 billion, representing an acceleration well beyond any prior first quarter on record in the VAB dataset, which covers TV media including cable TV, network TV, Spanish-language cable and network TV, spot TV, syndication TV, and streaming.

Seven brands enter TV for the first time

One of the more striking data points in VAB's analysis concerns brands that had never previously advertised on multiscreen TV. Seven pharma Rx brands launched their first TV campaigns between September and December 2025, spending a collective $207.6 million on the channel through March 2026, according to VAB analysis of Nielsen Ad Intel data.

Cobenfy Rx, a treatment for schizophrenia that received FDA approval in September 2024, spent $106.8 million on TV after launching its first campaign in September 2025 - by far the largest sum among the group. Auvelity Rx, approved for depression in August 2022, launched TV advertising the same month and spent $40.3 million. LEQEMBI Rx, an early Alzheimer's treatment approved in January 2023, began TV advertising in September 2025 and spent $16.7 million.

Three brands began TV campaigns in November 2025: Brukinsa Rx, a treatment for B-cell malignancies including lymphoma and leukemia (approved November 2019, spent $19.2 million); Ocrevus Rx, a multiple sclerosis treatment approved in March 2017 (spent $18.1 million); and Elahere Rx, an ovarian cancer treatment approved in November 2022 (spent $6.0 million). ENHERTU Rx, approved for various cancers including breast, lung, and stomach cancer in December 2019, launched TV advertising in September 2025 and spent $0.6 million.

The breadth of therapeutic areas represented - schizophrenia, depression, Alzheimer's, B-cell malignancies, multiple sclerosis, ovarian cancer, and various other cancers - suggests the shift was not confined to a single drug category but reflected a broader reorientation toward TV as a compliant advertising channel for complex prescription products.

Ad unit length: longer ads become the norm

Beyond spending levels, VAB's analysis tracks a measurable structural change in how pharma brands construct their TV commercials. The data show a sustained shift toward longer ad units, which VAB frames as evidence of brands proactively accommodating disclosure requirements - specifically, the need to include information about major side effects and contraindications.

In the six-month period from October 2024 through March 2025, ads longer than 30 seconds accounted for 76% of pharma Rx commercial units on national TV and streaming. In the equivalent period after the crackdown (October 2025 through March 2026), that share rose to 82%, according to VAB analysis of Nielsen Ad Intel data. Shorter ads - those 30 seconds or less - fell from 24% to 18% of total units.

The 60-second unit tells a particularly clear story. According to VAB's month-by-month analysis, the share of pharma Rx commercial units running at 60 seconds stood at 56% in August 2025. By March 2026, that share had risen to 63% - a seven-percentage-point increase over seven months. Viewed across the longer 27-month period from January 2024 through March 2026, the trend is consistent: the share of pharma Rx ad units longer than 30 seconds in Q1 increased from 74% in Q1 2024 to 82% in Q1 2026.

The prime time daypart shows closely aligned patterns. During prime time between January 2025 and March 2026, 60-second units accounted for a 59% average share, with the monthly breakdown rising from 56% in August 2025 to 63% in March 2026 - matching the overall national TV trajectory almost exactly, according to the VAB data. The alignment between prime time and total daypart suggests brands are not making creative decisions differently for premium slots; rather, the compliance-driven length adjustments apply uniformly.

Live sports, news, and entertainment

The trend toward longer ad units is consistent across content genres, though with varying magnitudes. In live sports programming, the year-over-year share of pharma Rx ad units longer than 30 seconds increased from 77% in Q1 2025 to 86% in Q1 2026, according to VAB analysis of Nielsen Ad Intel data - the most pronounced shift of any content category examined.

News programming showed a more modest change. The share of longer-than-30-second pharma ads in news programs moved from 77% to 79% between Q1 2025 and Q1 2026. In entertainment programming (defined by VAB as dramas, comedies, documentaries, and feature films, excluding live sports and news), the shift went from 78% to 82% over the same period.

Product categories and ad length

The differences in ad length across therapeutic categories are substantial, and reflect the relative complexity of disclosing side effects for different drug classes.

In Q1 2026, depression, HIV, tardive dyskinesia, bipolar disorder, and schizophrenia treatments each ran 100% of their TV commercial units at 60 seconds or longer, according to VAB analysis of Nielsen Ad Intel data. Alzheimer's treatments ran 99% of units at 60 seconds or longer; multiple sclerosis and pneumococcal treatments each reached 100%; geographic atrophy, hepatitis, and osteoporosis treatments were also at 100%.

Cancer treatments occupied a more mixed position. In Q1 2026, 38% of cancer drug ad units ran at 60 seconds, 29% at 75 seconds, and 33% at 90 seconds - meaning the category used a wide range of longer formats. Diabetes treatments split differently: 23% at 60 seconds and 77% at 75 seconds. AMD (age-related macular degeneration) treatments split 84% at 60 seconds and 16% at 75 seconds.

At the other end of the spectrum, categories using shorter units include asthma (53% of units at 30 seconds or shorter), migraines (56%), animal health (99%), dry eyes (95%), erectile dysfunction (96%), and alcoholism (100%), according to the VAB dataset. The divergence suggests that therapeutic areas with more complex safety profiles are choosing longer formats at a higher rate than those where the regulatory disclosure burden is lighter.

What this means for the marketing industry

The data carry direct implications for media planners, programmatic buyers, and brand managers working in the healthcare and pharmaceutical categories. PPC Land has followed the evolution of digital pharmaceutical advertising policy closely, including Google's December 2025 decision to allow Authorized Buyers to promote prescription drugs without platform-level certification in certain markets. That decision came just three months after the FDA's enforcement letters, and it moved in an opposite direction - reducing barriers to pharma promotion in digital environments even as the regulatory climate around broadcast DTC advertising tightened.

The combination creates an asymmetric regulatory environment. Digital pharma advertising operates across a patchwork of platform policies, while broadcast TV advertising is subject to federal disclosure rules enforced by the FDA directly. The September 2025 crackdown concentrated enforcement on digital and social - the FDA sent 59 warning letters for brand website content and 34 untitled letters for TV advertising - signalling a clear hierarchy of enforcement priority that brands appear to have factored into their media allocations.

For buyers, the consequence is practical. Brands seeking compliant, regulated environments for complex product advertising appear to have concluded that multiscreen TV - with its established disclosure norms - carries lower regulatory risk than digital placements that remain contested territory. The 53% spending increase and 11% rise in active brand count are large enough to constitute a structural shift, not a quarterly fluctuation.

PPC Land's coverage of the global TV advertising landscape has documented the ongoing migration of linear audiences toward streaming platforms. VAB's pharma spending data suggest that for regulated advertisers, the programmatic and streaming elements of multiscreen TV may be seen as comparably safe channels - particularly compared with social media and search, which lack the decades of established FDA oversight that governs broadcast advertising. The Video Advertising Bureau's own 2026 streaming analysis estimated that ad-supported streaming reached 209.4 million US viewers, a scale that makes it a natural extension of broadcast strategy for pharmaceutical advertisers.

The shift toward longer ad units may be the more durable consequence. It represents brands making a structural creative choice - building additional time into their spots to accommodate fuller disclosure of risks and side effects - that constrains execution while providing clearer compliance footing. The 60-second unit, already standard for pharma TV advertising, now commands an even higher share. More striking is the emergence of 75-second and 90-second formats as meaningful portions of the commercial mix in categories like cancer and obesity, suggesting that some brands are building substantially more time into their spots than the format had previously demanded.

The VAB analysis is available to VAB members and qualified marketers via theVAB.com. The underlying data sources are Nielsen Ad Intel (January 2023 through March 2026) and FDA.gov enforcement letter data as of September 12, 2025.

Timeline

  • 1997 - The FDA introduces the "adequate provision" framework for broadcast DTC drug advertising, allowing pharma companies to reference websites and toll-free numbers rather than reading full safety disclosures in TV commercials, creating what agencies later describe as a loophole
  • March 2017 - Ocrevus Rx receives FDA approval for multiple sclerosis; the drug does not begin TV advertising until November 2025
  • November 2019 - Brukinsa Rx receives FDA approval for B-cell malignancies; it also waits until November 2025 to launch TV advertising
  • August 2022 - Auvelity Rx receives FDA approval for depression; it launches its first TV campaign in September 2025
  • November 2022 - Elahere Rx receives FDA approval for ovarian cancer; it launches TV advertising in November 2025
  • January 2023 - LEQEMBI Rx receives FDA approval for early Alzheimer's; it launches TV advertising in September 2025
  • Q4 2023 - Pharma Rx multiscreen TV spend totals $1.66 billion, with 124 active brands
  • Q4 2024 - Pharma Rx multiscreen TV spend falls slightly to $1.64 billion (-1% year-over-year); 122 active brands (-2%); Q1 2025 spend stands at $1.60 billion (-7% year-over-year)
  • June 2025 - Google launches restricted drug term certification for healthcare advertisers in the United States, Canada, and New Zealand, adding a certification layer for personalized targeting using pharmaceutical terms
  • August 2025 - Google simplifies healthcare ad enforcement by deprecating the Restricted Medical Content label; pharma Rx 60-second ad unit share stands at 56% on national TV
  • September 9, 2025 - The White House issues a presidential memorandum directing HHS and the FDA to step up DTC pharmaceutical advertising enforcement; FDA sends more than 100 enforcement letters, including 59 warning letters for brand website content and 34 untitled letters for TV advertising; 96% of formal warning letters target digital and social platforms
  • September 2024 - Cobenfy Rx receives FDA approval for schizophrenia
  • September 2025 - Cobenfy Rx, Auvelity Rx, LEQEMBI Rx, and ENHERTU Rx launch first-ever TV campaigns; pharma Rx 60-second ad unit share rises to 59% on national TV
  • October 2025 - Google revises prescription drug advertising policy for the US, Canada, and New Zealand, creating distinct programmatic frameworks from other markets; pharma Rx 60-second unit share reaches 61%
  • November 2025 - Brukinsa Rx, Ocrevus Rx, and Elahere Rx launch first TV campaigns; pharma Rx 60-second ad unit share reaches 65% on national TV
  • December 2025 - Google extends programmatic freedom on prescription drug ads to Authorized Buyers without platform-level certification; pharma Rx 60-second unit share at 64%
  • Q4 2025 (full quarter) - Pharma Rx multiscreen TV spend reaches $1.86 billion (+13% year-over-year); 140 active Rx brands (+15%); seven first-time TV advertisers collectively spend $207.6 million from September 2025 through March 2026
  • January 2026 - Pharma Rx 60-second ad unit share reaches 68% on national TV, the highest monthly figure in the 27-month VAB dataset
  • Q1 2026 - Pharma Rx multiscreen TV spend reaches $3.09 billion (+94% year-over-year); 132 active Rx brands (+10%); share of ad units longer than 30 seconds reaches 82% on national TV
  • October 2025 - March 2026 (six-month combined) - Pharma Rx multiscreen TV spend totals $4.95 billion, up 53% year-over-year from $3.23 billion; 153 active brands, up 11%
  • March 2026 - VAB publishes streaming report finding 209.4 million US consumers using ad-supported streaming; pharma Rx 60-second unit share at 63% on national TV
  • May 2026 - VAB publishes "How has the FDA's crackdown on deceptive drug advertising affected multiscreen TV?" analysis drawing on Nielsen Ad Intel data through March 2026

Summary

Who: Pharma Rx brands across therapeutic categories including schizophrenia, depression, Alzheimer's, HIV, cancer, diabetes, multiple sclerosis, and others; the Video Advertising Bureau (VAB), which produced the analysis; and the FDA and HHS, which initiated enforcement under a White House directive.

What: Pharma Rx brands increased multiscreen TV advertising spend by 53% year-over-year in the six months after the FDA's September 2025 crackdown on deceptive drug advertising, spending $4.95 billion between October 2025 and March 2026. Seven brands entered TV for the first time during the period, collectively spending $207.6 million. Ad units longer than 30 seconds rose from 76% to 82% of all pharma commercial units on national TV. The share of 60-second ads increased from 56% in August 2025 to 63% by March 2026.

When: The FDA enforcement action occurred on September 9, 2025. The six-month spending acceleration covers October 2025 through March 2026. VAB published its analysis in May 2026, drawing on Nielsen Ad Intel data from January 2023 through March 2026.

Where: The data cover national multiscreen TV and streaming in the United States, including cable TV, network TV, Spanish-language cable and network TV, spot TV, syndication TV, and streaming. The FDA enforcement letters were directed at US pharmaceutical companies advertising in domestic media, with 96% of formal warning letters targeting digital and social platforms.

Why: The FDA's enforcement action concentrated 96% of its formal warning letters on digital and social platforms, effectively communicating to pharmaceutical advertisers that broadcast and multiscreen TV carried lower regulatory risk than digital channels. According to VAB, the regulatory clarity this provided spurred increased investment across multiscreen TV platforms. The simultaneous shift toward longer ad units reflects brands proactively accommodating FDA disclosure requirements for side effects and contraindications - a structural adaptation to stricter enforcement that is measurable in the commercial unit data.

Share this article
The link has been copied!